- Home
- BIIB vs TECK Comparison
BIIB vs TECK Comparison
Compare BIIB & TECK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- TECK
- Stock Information
- Founded
- BIIB 1978
- TECK 1913
- Country
- BIIB United States
- TECK Canada
- Employees
- BIIB N/A
- TECK N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- TECK
- Sector
- BIIB Health Care
- TECK
- Exchange
- BIIB Nasdaq
- TECK Nasdaq
- Market Cap
- BIIB 25.1B
- TECK 24.9B
- IPO Year
- BIIB 1991
- TECK N/A
- Fundamental
- Price
- BIIB $150.03
- TECK $44.08
- Analyst Decision
- BIIB Buy
- TECK Buy
- Analyst Count
- BIIB 27
- TECK 7
- Target Price
- BIIB $252.20
- TECK $64.86
- AVG Volume (30 Days)
- BIIB 1.4M
- TECK 2.2M
- Earning Date
- BIIB 02-11-2025
- TECK 10-24-2024
- Dividend Yield
- BIIB N/A
- TECK 1.68%
- EPS Growth
- BIIB 10.05
- TECK N/A
- EPS
- BIIB 11.06
- TECK 0.69
- Revenue
- BIIB $9,607,500,000.00
- TECK $12,329,841,958.00
- Revenue This Year
- BIIB N/A
- TECK N/A
- Revenue Next Year
- BIIB N/A
- TECK N/A
- P/E Ratio
- BIIB $13.56
- TECK $63.47
- Revenue Growth
- BIIB N/A
- TECK 114.29
- 52 Week Low
- BIIB $149.94
- TECK $36.50
- 52 Week High
- BIIB $268.30
- TECK $55.13
- Technical
- Relative Strength Index (RSI)
- BIIB 25.52
- TECK 38.26
- Support Level
- BIIB $153.69
- TECK $45.29
- Resistance Level
- BIIB $158.20
- TECK $47.86
- Average True Range (ATR)
- BIIB 3.58
- TECK 1.02
- MACD
- BIIB 0.16
- TECK -0.08
- Stochastic Oscillator
- BIIB 0.62
- TECK 9.48
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About TECK Teck Resources Ltd
Teck is a base metals miner with copper and zinc operations in Canada, the United States, Chile, and Peru. After selling its metallurgical coal business, copper is now its major commodity by EBITDA contribution, followed by zinc. Teck is a top-three zinc miner. Its major new copper mine in Chile at the majority-owned Quebrada Blanca 2, in partnership with Sumitomo, will drive an increase in Teck's attributable copper production by roughly 75%. Along with a number of additional copper growth options, Teck's strategy is to rebalance its portfolio to low-carbon metals such as copper. It sold its oil sands business in early 2023 and its coal business in mid-2024.